Whalesbook
Zydus Lifesciences Faces ₹3.28 Crore Tax Demand, Plans Appeal
Zydus Lifesciences Limited has received a tax demand order for ₹3.28 crore from the Assistant Commissioner of State Tax in Gujarat. The order pertains to the fiscal year 2019-20 and concerns alleged inadmissible Input Tax Credit, including the principal amount, interest, and penalty.
The company announced on March 24, 2026, that it plans to appeal this decision. Zydus Lifesciences expressed confidence in the appeal's merits, anticipating a favorable outcome, and stated that no material financial impact is expected.
Company Confident in Contesting Demand
Zydus Lifesciences views the tax demand critically and has decided to contest it. Management has conveyed strong belief in their position, expecting a positive resolution from the appellate authorities. The company has asserted that there will be no material financial impact from this demand.
History of Tax Disputes
This tax demand follows a pattern of similar issues faced by Zydus Lifesciences concerning Input Tax Credit or CENVAT credit. In December 2025, the company received a ₹2.8 crore GST demand for FY 2018-19 over alleged inadmissible ITC, also planning an appeal. In September 2025, a ₹3.35 crore demand was confirmed related to CENVAT credit on sales commissions paid to foreign entities, which Zydus also contested. Earlier in January 2025, a ₹10.12 million penalty was imposed following a GST audit for the period July 2017 to March 2021, which the company intended to challenge.
Next Steps for Zydus Lifesciences
Zydus Lifesciences will formally initiate the appeal process against the latest tax demand order. The company's management will focus on preparing its case for the appellate authorities. Financial planning will account for the contingent nature of this liability until the appeal is resolved.
Potential Risks
The primary risk is the potential for an unfavorable outcome in the appeal process, although the company appears confident. Tax litigation can sometimes lead to unexpected financial implications and diversion of management attention.
Industry Context: Tax Litigation in Pharma
Zydus Lifesciences operates in a sector where tax disputes are not uncommon. Peers like Divi's Laboratories faced a substantially larger tax demand of ₹570.51 crore for FY22-23 related to transfer pricing. Sanofi India also received a ₹2.37 crore tax demand concerning Input Tax Credit claims in early 2026. These instances highlight the prevalent nature of tax litigation within the Indian pharmaceutical industry, often related to ITC and transfer pricing issues.
Company Overview
Zydus Lifesciences is India's fourth-largest pharmaceutical company, with global operations in approximately 55 countries. Its business spans pharmaceuticals, including APIs and formulations, and consumer wellness products.
What to Monitor Next
Investors should monitor the progress and timelines of Zydus Lifesciences' appeal against the ₹3.28 crore tax demand. Updates from the company regarding court hearings or resolutions will be significant. Commentary from management on future tax strategies or precedents, and further developments in similar tax disputes involving other pharmaceutical peers, should also be noted.